Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2021
>
InnoCare Announces Approval of Clinical Trial of TYK2 Inhibitor ICP-332 in China
InnoCare Announces Approval of Clinical Trial of TYK2 Inhibitor ICP-332 in China
Read also
CorriXR Therapeutics
CorriXR Therapeutics Announces Publication of Preclinical Data Demonstrating Potential of CRISPR-Directed Gene Editing to Overcome Drug Resistance in Solid Tumors
Medicxi unveils €500m fund for asset-centric biotechs
London-headquartered investment firm Medicxi has unveiled a €500m ($580m) fund to back innovative biotechs
FDA confirms Animal Rule
FDA confirms Animal Rule and PRV potential for Galidesivir in Marburg
AI-Driven Method
AI-Driven Method IDs Alzheimer Disease and Related Dementias in Primary Care
